AUTHOR=Dong Jie , Zhang Jinli , Pan Hongming , Wang Chongwei , Sheng Jin 

TITLE=SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1521828

DOI=10.3389/fimmu.2025.1521828

ISSN=1664-3224